LegalView Informs Americans of Potentially Dangerous Risk of Asbestos Exposure in Home Attic Insulation

(PRLEAP.COM) Denver, CO - LegalView reported the details of the risk of asbestos-riddled insulation in home attics across the country. According to news reports, homes built between the 1920s and 1980s are likely to contain insulation derived from vermiculite that was contaminated with asbestos. Asbestos is a mineral that, when inhaled, causes a deadly form of lung cancer to develop on the lining of the lungs. The cancer, known as mesothelioma, can remain dormant within the body for decades before symptoms become apparent, at which point the cancer becomes untreatable. Individuals who suffer from this cancer are advised to speak with an experienced mesothelioma attorney to better understand the potential for developing a mesothelioma lawsuit .

There are currently no treatments available that can cure mesothelioma cancer. Those who may have been exposed to asbestos should seek medical attention immediately. Additionally, contacting a mesothelioma law firm that can provide a list of knowledgeable mesothelioma lawyers will help with any potential litigation that could provide monetary compensation to assist with the costly medical bills commonly associated with the condition.

In addition to mesothelioma, LegalView offers other information portals on a variety of legal topics ranging from the latest on the proton pump inhibitor drugs to information on Cipro antibiotics to the latest statistics on truck accidents. Proton pump inhibitors (PPIs) are drugs used to suppress gastric acids within the stomach, which may cause ulcers, stomach infections and other related conditions. Recently, these drugs have been linked to a severe risk that may cause medical harm to patients. The PPI side effects includes an increased risk of bone fracture as they may not only reduce gastric acids, but may also suppress calcium absorption, according to a study from the Canadian Medical Association Journal.

Cipro is part of a family of antibiotics known as the fluoroquinolone family. Cipro treats bacterial infections such as bronchitis or pneumonia. The U.S. Food and Drug Administration (FDA) recently increased the warning label of all fluoroquinolone drugs a black box labeling because of the risks associated with consumption of any of the antibiotics. The drugs have been linked to tendonitis and Achilles tendon rupture among patients. To learn more about the drug’s side effects or how to become involved in a potential Cipro class action lawsuit , visit http://cipro.legalview.com/.

LegalView also offers information on truck accidents, the most costly and fatal vehicular accidents that occur, according to reports from the U.S. Department of Transportation (DOT). If an individual has been involved in a truck accident, they may be able to receive free legal consultation on a truck accident lawsuit from a knowledgeable lawyer.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation’s most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com’s superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.
Contact Information
Katie Kelley
LegalView.com
720-771-3246
Email LegalView.com

About This News Release

If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.

Share this News
PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy